Logo

Gilead Amends Agreement with Galapagos for Development and Commercialization of Jyseleca (filgotinib)

Share this

Gilead Amends Agreement with Galapagos for Development and Commercialization of Jyseleca (filgotinib)

Shots:

  • Following the FDA Type A meeting- Gilead will not pursue the approval of Jyseleca for RA in the US. Galapagos will be solely responsible in EU for Jyseleca (200/100mg) in RA and UC + all future indications for which Gilead will receive royalties on EU sales initiating in 2024
  • Galapagos to receive $194.6M- which will be split b/w $133.7M in 2021 & $60.8M in 2022 for the ongoing development and accelerated commercial buildout in the EU
  • Additionally- Galapagos will assume responsibility for ongoing clinical trials evaluating filgotinib in RA. Gilead will retain commercial rights for filgotinib outside the EU- including in Japan where filgotinib has recently been approved and is co-marketed with Eisai

 ­ Ref: GlobeNewswire | Image: Canva

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions